Evidence map›Paper›PMID 35933420›Full record

ArticleJournal of neuroinflammation2022

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity.

Elizabeth E Evans, Vikas Mishra, Crystal Mallow, Elaine M Gersz, Leslie Balch, Alan Howell, Christine Reilly, Ernest S Smith, Terrence L Fisher, Maurice Zauderer

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Semaphorins and Their Role in Neuropathic Pain.Life (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Elizabeth E EvansVaccinex, Inc., Research, Rochester, NY, USA.ORCID https://orcid.org/0000-0002-9287-9221
Vikas MishraVaccinex, Inc., Research, Rochester, NY, USA.ORCID https://orcid.org/0000-0002-4555-0132
Crystal MallowVaccinex, Inc., Research, Rochester, NY, USA.
Elaine M GerszVaccinex, Inc., Research, Rochester, NY, USA.
Leslie BalchVaccinex, Inc., Research, Rochester, NY, USA.
Alan HowellVaccinex, Inc., Research, Rochester, NY, USA.
Christine ReillyVaccinex, Inc., Research, Rochester, NY, USA.
Ernest S SmithVaccinex, Inc., Research, Rochester, NY, USA.
Terrence L FisherVaccinex, Inc., Research, Rochester, NY, USA.ORCID https://orcid.org/0000-0001-9326-6606
Maurice ZaudererVaccinex, Inc., Research, Rochester, NY, USA. mzauderer@vaccinex.com.ORCID http://orcid.org/0000-0002-4253-9165
Vaccinex (United States) · USUniversity of Rochester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe close interaction and interdependence of astrocytes and neurons allows for the possibility that astrocyte dysfunction contributes to and amplifies neurodegenerative pathology. Molecular pathways that trigger reactive astrocytes may represent important targets to preserve normal homeostatic maintenance and modify disease progression.

methodsSemaphorin 4D (SEMA4D) expression in the context of disease-associated neuropathology was assessed in postmortem brain sections of patients with Huntington's (HD) and Alzheimer's disease (AD), as well as in mouse models of HD (zQ175) and AD (CVN; APPSwDI/NOS2

resultsWe report here that SEMA4D is upregulated in neurons during progression of neurodegenerative diseases and is a trigger of reactive astrocytes. Evidence of reactive astrocytes in close proximity to neurons expressing SEMA4D is detected in brain sections of patients and mouse models of HD and AD. We further report that SEMA4D-blockade prevents characteristic loss of GABAergic synapses and restores spatial memory and learning in CVN mice, a disease model that appears to reproduce many features of AD-like pathology including neuroinflammation. In vitro mechanistic studies demonstrate that astrocytes express cognate receptors for SEMA4D and that ligand binding triggers morphological variations, and changes in expression of key membrane receptors and enzymes characteristic of reactive astrocytes. These changes include reductions in EAAT-2 glutamate transporter and glutamine synthetase, key enzymes in neurotransmitter recycling, as well as reduced GLUT-1 glucose and MCT-4 lactate transporters, that allow astrocytes to couple energy metabolism with synaptic activity. Antibody blockade of SEMA4D prevented these changes and reversed functional deficits in glucose uptake.

conclusionsCollectively, these results suggest that SEMA4D blockade may ameliorate disease pathology by preserving normal astrocyte function and reducing the negative consequences of reactive astrogliosis.

Indexed as

Alzheimer DiseaseAstrocytesAnimalsAntigens, CDBrainDisease Models, AnimalHumansMiceNeuronsSemaphorinsAntigens, CDCD100 antigenSemaphorinsAlzheimer’s diseaseDisease modelsHuntington’s diseaseMetabolic reprogrammingNeurodegenerationNeurotransmitter recyclingPathogenesisReactive astrocytesSemaphorin

Identifiers

PMID35933420
PMCPMC9356477
OpenAlexW4289981917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.